# OnCo record nct03319628 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03319628/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03319628", "NCT03319628" ;
  schema:name "First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b"@en ;
  schema:description "A phase 1/2 trial of upifitamab rilsodotin in ovarian cancer and non-small-cell lung cancer, run by Mersana Therapeutics, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03319628/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03319628> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2017-12-12" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/upifitamab-rilsodotin/> ;
  onco:companies <https://onco.cc/companies/mersana/> .